[youtube id=”BeoBY0dXIEI” width=”600″ height=”350″ autoplay=”no” api_params=”” class=””] Isatuximab for multiple myeloma – promising results and next steps :Thomas Martin, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses the use of monoclonal antibody therapy in multiple myeloma (MM). Daratumumab and elotuzumab are already approved and according to Prof Martin, the next monoclonal antibody to be…….

[youtube id=”29FSSybCEgs” width=”600″ height=”350″ autoplay=”no” api_params=”” class=””]
T-CELL| Engineered cells to target multiple myeloma | Dr Kochenderfer talks to ecancertv at ASH 2015 about the promising results of a phase I clinical trial that provides evidence that adoptive T cell therapy may work in patients with advanced multiple myeloma. (2016)

[youtube id=”z6qRxIZWidU” width=”600″ height=”350″ autoplay=”no” api_params=”” class=””] T-CELL|  the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Keith Stewart, MB, ChB, from Mayo Clinic, Scottsdale, AZ, discusses data from a phase 1 clinical trial investigating an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy for patients with multiple Myeloma [youtube id=”Sglpu9Bz724″ width=”600″ height=”350″ autoplay=”no” api_params=”” class=””] T-CELL |Myeloma 2016: Panel discussion on gene modified T-cells van Borrello, MD from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Batlimore, MD discusses the highlights in immunotherapy and in particular CAR T-cells for multiple myeloma (MM) from the Myeloma 2016 meeting held in Boston, MA with Edward Stadtmauer, MD from the University
[youtube id=”Wx3D29Jlf5M” width=”600″ height=”350″ autoplay=”no” api_params=”” class=””] Myeloma 2016: Panel discussion on novel treatments: The Myeloma 2016 meeting, was held in Boston, MA, between 22–24 April. Keith Stewart MB, ChB from the Mayo Clinic, discusses the day 1 highlights with Sagar Lonial, MD of the Winship Cancer Institute, Kenneth Anderson, MD of the Dana-Farber Cancer Institute, and Leif Bergsagel, MD of the Mayo Clinic. Here the experts discuss the possible targets of cellular immunotherapy, using CAR T-cells and BiT